PriceTargets.com logo

Palvella Therapeutics - PVLA Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $121.77
  • Forecasted Upside: 29.82%
  • Number of Analysts: 14
  • Breakdown:
  • 1 Sell Ratings
  • 0 Hold Ratings
  • 11 Buy Ratings
  • 2 Strong Buy Ratings
$93.80 As of 12/4/2025 05:00 PM ET
▲ +1.89 (2.06%)

This chart shows the closing price for PVLA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Palvella Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PVLA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PVLA

Analyst Price Target is $121.77
▲ +29.82% Upside Potential
This price target is based on 14 analysts offering 12 month price targets for Palvella Therapeutics in the last 3 months. The average price target is $121.77, with a high forecast of $200.00 and a low forecast of $45.00. The average price target represents a 29.82% upside from the last price of $93.80.

This chart shows the closing price for PVLA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 14 polled investment analysts is to buy stock in Palvella Therapeutics. This rating changed within the last month from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/12/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/10/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/9/2024
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/9/2025
  • 1 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/7/2025
  • 1 strong buy ratings
  • 10 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/5/2025
  • 1 strong buy ratings
  • 11 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
11/4/2025
  • 2 strong buy ratings
  • 10 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
12/4/2025

Latest Recommendations

  • 2 strong buy ratings
  • 11 buy ratings
  • 0 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
12/4/2025Craig HallumInitiated CoverageBuy$175.00
12/1/2025Weiss RatingsReiterated RatingSell (D) ➝ Sell (D)
11/25/2025Weiss RatingsReiterated RatingSell (D) ➝ Sell (D)
11/24/2025Stifel NicolausBoost TargetBuy ➝ Buy$87.00 ➝ $145.00
11/19/2025Raymond James FinancialUpgradeOutperform ➝ Strong-Buy$92.00 ➝ $143.00
11/13/2025Canaccord Genuity GroupBoost TargetBuy ➝ Buy$90.00 ➝ $148.00
11/13/2025Chardan CapitalReiterated RatingBuy ➝ Buy$110.00
11/11/2025OppenheimerReiterated RatingOutperform ➝ Outperform
11/10/2025Truist FinancialBoost TargetBuy ➝ Buy$80.00 ➝ $105.00
11/7/2025Chardan CapitalBoost TargetBuy ➝ Buy$73.00 ➝ $110.00
11/6/2025TD CowenBoost TargetBuy ➝ Buy$65.00 ➝ $97.00
11/6/2025Cantor FitzgeraldBoost TargetOverweight ➝ Overweight$120.00 ➝ $200.00
11/6/2025HC WainwrightBoost TargetBuy ➝ Buy$95.00 ➝ $190.00
10/9/2025Canaccord Genuity GroupBoost TargetBuy ➝ Buy$66.00 ➝ $90.00
10/8/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
10/7/2025Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$120.00
10/2/2025Truist FinancialBoost TargetBuy ➝ Buy$56.00 ➝ $80.00
9/27/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
9/26/2025Chardan CapitalBoost TargetBuy ➝ Buy$60.00 ➝ $73.00
9/25/2025HC WainwrightBoost TargetBuy ➝ Buy$75.00 ➝ $95.00
9/24/2025Stifel NicolausBoost TargetBuy ➝ Buy$60.00 ➝ $80.00
9/9/2025OppenheimerInitiated CoverageOutperform$85.00
8/19/2025Canaccord Genuity GroupBoost TargetBuy ➝ Buy$52.00 ➝ $66.00
8/15/2025HC WainwrightBoost TargetBuy ➝ Buy$38.00 ➝ $75.00
8/15/2025Chardan CapitalBoost TargetBuy ➝ Buy$50.00 ➝ $60.00
8/5/2025Raymond James FinancialSet TargetOutperform$54.00
8/4/2025Lifesci CapitalInitiated CoverageOutperform$90.00
7/21/2025Truist FinancialInitiated CoverageBuy$56.00
5/16/2025Canaccord Genuity GroupLower TargetBuy ➝ Buy$53.00 ➝ $52.00
4/30/2025HC WainwrightReiterated RatingBuy ➝ Buy$38.00 ➝ $38.00
4/9/2025Chardan CapitalInitiated CoverageBuy$50.00
4/1/2025HC WainwrightReiterated RatingBuy ➝ Buy$38.00 ➝ $38.00
3/26/2025Stifel NicolausInitiated CoverageBuy$45.00
3/25/2025Jones TradingInitiated CoverageBuy$45.00
3/24/2025Jones TradingUpgradeStrong-Buy
3/7/2025ScotiabankInitiated CoverageSector Outperform$50.00
2/26/2025Canaccord Genuity GroupReiterated RatingBuy ➝ Buy$39.00 ➝ $39.00
2/20/2025Canaccord Genuity GroupInitiated CoverageBuy$39.00
2/11/2025HC WainwrightReiterated RatingBuy ➝ Buy$38.00 ➝ $38.00
2/5/2025TD CowenInitiated CoverageBuy$44.00
1/10/2025HC WainwrightReiterated RatingBuy ➝ Buy$38.00 ➝ $38.00
1/3/2025HC WainwrightReiterated RatingBuy ➝ Buy$38.00 ➝ $38.00
12/26/2024HC WainwrightInitiated CoverageBuy$38.00
12/18/2024Cantor FitzgeraldInitiated CoverageOverweight
(Data available from 12/4/2020 forward)

News Sentiment Rating

0.55 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 10 very positive mentions
  • 14 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/8/2025
  • 11 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/7/2025
  • 6 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/7/2025
  • 2 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/6/2025
  • 9 very positive mentions
  • 19 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/5/2025
  • 7 very positive mentions
  • 28 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/5/2025
  • 5 very positive mentions
  • 14 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/4/2025
  • 15 very positive mentions
  • 28 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
12/4/2025

Current Sentiment

  • 15 very positive mentions
  • 28 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Palvella Therapeutics logo
Palvella Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc., formerly known as Pieris Pharmaceuticals Inc., is based in WAYNE, Pa.
Read More

Today's Range

Now: $93.80
Low: $90.09
High: $95.00

50 Day Range

MA: $79.06
Low: $59.59
High: $102.79

52 Week Range

Now: $93.80
Low: $11.17
High: $106.71

Volume

198,380 shs

Average Volume

244,702 shs

Market Capitalization

$1.11 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Palvella Therapeutics?

The following sell-side analysts have issued reports on Palvella Therapeutics in the last year: Canaccord Genuity Group Inc., Cantor Fitzgerald, Chardan Capital, Craig Hallum, HC Wainwright, Jones Trading, Lifesci Capital, Oppenheimer Holdings, Inc., Raymond James Financial, Inc., Scotiabank, Stifel Nicolaus, TD Cowen, Truist Financial Corporation, and Weiss Ratings.
View the latest analyst ratings for PVLA.

What is the current price target for Palvella Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Palvella Therapeutics in the last year. Their average twelve-month price target is $121.77, suggesting a possible upside of 29.8%. Cantor Fitzgerald has the highest price target set, predicting PVLA will reach $200.00 in the next twelve months. Jones Trading has the lowest price target set, forecasting a price of $45.00 for Palvella Therapeutics in the next year.
View the latest price targets for PVLA.

What is the current consensus analyst rating for Palvella Therapeutics?

Palvella Therapeutics currently has 1 sell rating, 11 buy ratings and 2 strong buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe PVLA will outperform the market and that investors should add to their positions of Palvella Therapeutics.
View the latest ratings for PVLA.

What other companies compete with Palvella Therapeutics?

Other companies that are similar to Palvella Therapeutics include NewAmsterdam Pharma, Crinetics Pharmaceuticals, Scholar Rock, Arcellx and Lantheus. Learn More about companies similar to Palvella Therapeutics.

How do I contact Palvella Therapeutics' investor relations team?

Palvella Therapeutics' physical mailing address is 225 Franklin Street 26th Floor, Boston MA, 02110. The company's listed phone number is 857-246-8998 and its investor relations email address is [email protected]. The official website for Palvella Therapeutics is www.pieris.com. Learn More about contacing Palvella Therapeutics investor relations.